Abstract 4370885: Outcomes of Tirzepatide vs Semaglutide in Patients with Type 2 Diabetes and Heart Failure with Preserved Ejection Fraction: A Retrospective Cohort Analysis

作者
Abdulrahman Murshid,Maan A. Awad,Syed Muzzammil Ahmad,Saud Alawad,Harshith S. Thyagaturu
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:152 (Suppl_3) 被引量:1
标识
DOI:10.1161/circ.152.suppl_3.4370885
摘要

Background: Semaglutide, a GLP-1 receptor agonist, has demonstrated benefit in patients with heart failure with preserved ejection fraction (HFpEF). Tirzepatide, a dual GIP/GLP-1 receptor agonist with superior metabolic effects including weight loss, may provide additional advantages. Given limited head-to-head data, we evaluated clinical outcomes associated with Tirzepatide versus Semaglutide in patients with type 2 diabetes (T2D) and HFpEF. Methods: A retrospective, multicenter cohort study was conducted using TriNetX, a federated network of deidentified electronic health records from over 180 healthcare organizations. Adults with T2D and HFpEF (defined as left ventricular ejection fraction >40%) who initiated either Tirzepatide or Semaglutide between June 2022 and April 2024 were identified. After assessing baseline characteristics, 1:1 propensity score matching was performed to balance cohorts. The primary outcome was all-cause mortality. Secondary outcomes included new-onset atrial fibrillation/flutter, hospitalizations, episodes of acute-on-chronic diastolic heart failure, and intravenous diuretic use. Results: Among 14,157 patients on Semaglutide and 2,222 on Tirzepatide, 2,222 matched pairs were analyzed. All-cause mortality occurred in 81 patients treated with Tirzepatide versus 108 in the Semaglutide group (3.7% vs. 4.9%; risk difference -1.2%; 95% CI, -2.4 to -0.0; p =0.046). There were no significant differences in new-onset atrial fibrillation/flutter (3.3% vs. 3.4%; p =0.908), hospitalizations (3.1% vs. 3.0%; p =0.574), acute-on-chronic diastolic HF episodes (3.3% vs. 3.3%; p =0.944), or intravenous diuretic use (4.4% vs. 5.4%; p =0.116). Conclusions: In this real-world cohort of patients with T2D and HFpEF, Tirzepatide was associated with a statistically significant reduction in all-cause mortality compared to Semaglutide, without significant differences in other clinical outcomes. These findings support the potential cardiovascular benefit of Tirzepatide in this population and highlight the need for prospective studies to validate its long-term effects.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI65的应助被ice采纳,获得10
1秒前
感动如音完成签到 ,获得积分10
4秒前
木木完成签到,获得积分10
5秒前
monkeykey完成签到 ,获得积分10
5秒前
流星雨完成签到 ,获得积分10
6秒前
HHH完成签到 ,获得积分10
8秒前
默默翠霜完成签到,获得积分10
10秒前
完美幻桃完成签到,获得积分10
11秒前
俏皮诺言完成签到,获得积分10
12秒前
mdJdm完成签到 ,获得积分10
13秒前
123完成签到,获得积分10
16秒前
学术文献互助完成签到,获得积分0
16秒前
乐人完成签到 ,获得积分10
19秒前
佳佳完成签到 ,获得积分10
20秒前
pingbaby完成签到 ,获得积分10
20秒前
Sophia完成签到 ,获得积分10
21秒前
易道聚焦完成签到,获得积分10
23秒前
折耳根拌香菜完成签到 ,获得积分10
27秒前
linn1完成签到 ,获得积分10
28秒前
科研一坤年完成签到,获得积分10
28秒前
豆丁小猫完成签到,获得积分10
29秒前
万历十五年完成签到,获得积分10
29秒前
老辈子莫搞完成签到,获得积分10
30秒前
顺利的雨竹完成签到,获得积分10
33秒前
xiaxia42完成签到 ,获得积分0
35秒前
Ya完成签到 ,获得积分10
35秒前
Waboss完成签到,获得积分10
36秒前
36秒前
zcd完成签到 ,获得积分10
37秒前
日暮里123完成签到 ,获得积分10
37秒前
寻遇完成签到,获得积分10
38秒前
gdgd完成签到,获得积分10
38秒前
爱撒娇的蝴蝶完成签到 ,获得积分10
39秒前
39秒前
快乐雁风完成签到 ,获得积分10
40秒前
温暖冬日完成签到,获得积分10
41秒前
lxxxx完成签到 ,获得积分10
42秒前
假装超人会飞完成签到,获得积分10
42秒前
房杨发布了新的文献求助10
44秒前
eagletyr完成签到 ,获得积分10
45秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180097
求助须知:如何正确求助?哪些是违规求助? 9570230
关于积分的说明 21808841
捐赠科研通 7776113
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479013